Skip to main content
Premium Trial:

Request an Annual Quote

Intermountain Precision Genomics ICG100 Panel Expansion

Intermountain Precision Genomics announced today the expansion of the ICG100 panel, a test which identifies mutations, and then targets mutations with a personalized therapy. The panel expansion includes 162 genes often associated in cancer pathways. The panel is approved for late stage cancer patients who have failed to receive results from a traditional treatment method.